Exact Sciences Corporation (EXAS)

Market Cap	11.98B
Revenue (ttm)	2.08B
Net Income (ttm)	-623.51M
Shares Out	179.23M
EPS (ttm)	-3.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,987
Open	67.61
Previous Close	67.11
Day's Range	66.59 - 67.88
52-Week Range	29.27 - 76.94
Beta	1.42
Analysts	Buy
Price Target	77.76 (+16.3%)
Earnings Date	Apr 25, 2023

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 6,420
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS

Financial Performance

In 2022, Exact Sciences's revenue was $2.08 billion, an increase of 17.95% compared to the previous year's $1.77 billion. Losses were -$623.51 million, 4.68% more than in 2021.

Analyst Forecast

According to 26 analysts, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $77.76, which is an increase of 16.30% from the latest price.

Price Target

$77.76

(16.30% upside)

Analyst Consensus: Buy